Newsroom · Grand Junction

Does Medicare Cover Wegovy or Zepbound for Weight Loss?

As of six weeks ago, yes — for a $50 monthly copay, under a CMS demonstration with a specific drug list, three clinical doors, and an expiration date.

Medicare On Main Data Desk

Published August 12, 2026 · 9 min read · Reviewed by Brian Penner

For about two years, the honest answer to this question was a flat no, and it was an uncomfortable one to give. A federal statute has long kept Medicare drug plans from covering a medication used for weight loss, and I had a lot of conversations in Grand Junction that ended with a retiree doing the math on paying cash indefinitely and deciding against it.

That changed on July 1, 2026. CMS launched a short-term demonstration — the Medicare GLP-1 Bridge — that provides eligible Part D beneficiaries access to certain GLP-1 drugs for a $50 copay. It is not a permanent benefit, it is not in your plan's formulary, and it doesn't work the way anything else in Part D works. Here's what's actually in it.

What the Medicare GLP-1 Bridge is

Start with the structure, because it explains every strange detail further down. The Bridge is a demonstration — CMS is running it under longstanding authority to test changes in how Medicare pays for things. It operates, in CMS's words, "outside of the Medicare Part D benefit's coverage and payment flow." Your drug plan doesn't carry the risk and doesn't have to opt in. In 2026, CMS is running prior authorization, claims, and pharmacy payment through a single central processor instead of through the plans.

Practically, that means the Bridge is not a reason to choose one drug plan over another. It sits on top of whatever eligible Part D coverage you already have, everywhere in the country.

Which drugs are covered — and why Ozempic isn't one of them

This is the part worth reading twice, because the brand people ask about is not on the list. Under the Bridge, an eligible GLP-1 means one of these products when used to reduce excess body weight and maintain weight reduction:

• Foundayo (tablet)
• Wegovy (injection or tablet)
• Zepbound — KwikPen only. Medicare.gov is explicit that the program doesn't cover single-dose Zepbound vials or pens.

That last bullet is not a technicality. Two prescriptions for the same drug can land on opposite sides of the $50 depending on the device. Before you get to the pharmacy counter, confirm the exact product and form your prescriber sent.

And the separate track: type 2 diabetes, moderate-to-severe obstructive sleep apnea, and MASH — noncirrhotic metabolic dysfunction-associated steatohepatitis — are indications eligible for regular Part D coverage. CMS says beneficiaries with those diagnoses can get GLP-1s through their Part D plan and are therefore ineligible for the Bridge, even if they'd otherwise meet the clinical criteria. Whether your particular plan covers your particular drug for one of those conditions is a formulary question, and the answer varies plan by plan. Check yours on Medicare Plan Compare.

Who qualifies

You need eligible Medicare drug coverage, and your prescriber has to attest on a prior authorization that you meet one of three clinical profiles at the time you start GLP-1 therapy:

Source: CMS: Medicare GLP-1 Bridge — Information for Providers · Medicare.gov: Weight loss drugs. You must be 18 or older.

There's a fourth requirement that isn't about a number: your provider must certify that you're taking the drug in combination with ongoing lifestyle modification including structured nutrition and physical activity, consistent with the FDA-approved label. CMS built that into the attestation. This is not a program you get by asking for it.

Two exclusions to know before you get your hopes up. If you already receive GLP-1 drugs covered through your Part D plan, you're not eligible for the Bridge — you keep getting them the way you have been. And the diabetes / sleep apnea / fatty liver disease route above disqualifies you from the Bridge specifically.

What the $50 does and doesn't buy

Because the Bridge lives outside Part D, the ordinary Part D rules simply don't reach it. Four consequences, and the second one is the one I'd want a client to hear from me rather than discover in December:

Source: CMS: Medicare GLP-1 Bridge (program FAQs).

The out-of-pocket point deserves a sentence of its own. In 2026, everything you spend on covered Part D drugs stops at $2,100 for the year — that cap is the best thing to happen to Medicare drug coverage in a long time, and I've written about how it actually works. Bridge spending is invisible to it. Twelve months of $50 copays is $600 that sits entirely outside your cap math, on top of whatever your regular prescriptions cost. Budget it as a separate line, not as progress toward a ceiling.

Which kinds of coverage count

The Bridge is keyed to your type of Medicare drug coverage, not to your carrier. Eligible: a standalone Part D prescription drug plan, a Medicare Advantage coordinated care plan that includes drug coverage — HMO, HMOPOS, and local or regional PPO — a Special Needs Plan, an employer or union group waiver plan, and the Limited Income Newly Eligible Transition program. Dually eligible beneficiaries in those plan types can participate too.

Not eligible on their own: private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans — unless you also carry a standalone drug plan. And if you have Original Medicare with a supplement but never enrolled in Part D, there's nothing for the Bridge to attach to. That last case is more common around here than you'd think, and it's usually worth fixing for reasons that have nothing to do with weight-loss drugs.

How to start it

1. Talk to your prescriber about whether a GLP-1 is clinically appropriate for you. That conversation comes first and it isn't ours to have — an insurance agent has no role in a BMI-and-comorbidity determination.
2. Your provider sends the prescription to the pharmacy and completes the prior authorization when it's requested, attesting to the criteria and the lifestyle program.
3. Bring your Medicare Number. The pharmacy may ask for it, or for the last four digits of your Social Security Number, to process the claim.
4. Watch for the letter. Medicare mails confirmation that the drug is covered under the Bridge.
5. Note the expiration date. Your prior authorization holds through refills and dose changes until December 31, 2027 unless you switch to a different GLP-1 — at which point it starts over.
6. Questions on eligibility or a pending authorization? Call 1-800-MEDICARE (TTY 1-877-486-2048), or check the screening tool on Medicare.gov.

One caution on the alternatives. Medicare.gov points people who don't qualify toward cash-price comparison sites, and it attaches a warning worth repeating: discount cards aren't creditable coverage, and when you use one instead of your Medicare plan, what you spend doesn't count toward your deductible or your out-of-pocket maximum. Fine as a price check. Not a substitute for coverage.

Why this lands hard in Mesa County

The eligibility criteria are written in the language of exactly the conditions our county carries. Here's the local picture:

Chronic-condition rates among Mesa County, Colorado adults

Source: CDC PLACES, 2023 — via the Medicare On Main Data Desk. Model-based prevalence among adults, 2023.

Obesity runs at 29.8% of Mesa County adults and high blood pressure at 26.6% — and "uncontrolled hypertension" is one of the three diagnoses that opens the BMI-30 door. Coronary heart disease sits at 5.2%, and a previous heart attack opens the BMI-27 door. A meaningful number of people reading this are already inside the criteria and don't know the program exists.

Note the flip side, too. Diabetes prevalence here is 8.1%, and a type 2 diagnosis takes you out of the Bridge and back to your plan's formulary. Two neighbors with the same weight and the same prescription can end up on completely different tracks.

How we know all this: the Medicare On Main Data Desk frames every article with public data — here, the CMS Medicare GLP-1 Bridge program FAQs and the CMS provider FAQs for the July 1, 2026–December 31, 2027 demonstration window, the $50 copay, the covered drug list, the BMI-based clinical criteria, the lifestyle-program attestation, the eligible and ineligible plan types, and the statements that the Part D deductible doesn't apply, that no part of the copay counts toward true out-of-pocket costs, and that there is no low-income subsidy on these drugs; Medicare.gov's weight-loss drugs page for the beneficiary-facing eligibility screen, the Zepbound KwikPen limitation, the prior-authorization duration and the discount-card caveat; CMS's November 14, 2025 cost figures for the $283 2026 Part B deductible and the $2,100 Part D out-of-pocket cap; and Mesa County health figures from CDC PLACES (2023). Naming the drugs CMS lists is description, not endorsement, and nothing here is a recommendation to take or avoid a medication — that's between you and your prescriber. This is education, not advice; confirm your plan, costs, and eligibility with a licensed agent or Medicare.gov. We take no payment from any carrier to feature a plan.